Association Between Iron and Cholesterol in Neuroblastomas
| Autor: | Sang Y. Lee, James R. Connor, Junjia Zhu, Cara Lynne Schengrund, Becky Slagle-Webb |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Iron Iron Chelating Agents Neuroblastoma chemistry.chemical_compound Cell Line Tumor medicine Humans neoplasms Chemistry Cholesterol Anticholesteremic Agents Cancer Lipid metabolism General Medicine medicine.disease In vitro Deferoxamine Oncology Simvastatin Cancer cell Cancer research lipids (amino acids peptides and proteins) medicine.drug |
| Zdroj: | Anticancer Research. 41:2795-2804 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.15060 |
| Popis: | Background/aim Neuroblastoma is the most common childhood extracranial solid malignancy. Although cancer cells need iron and lipids for active cell division, possible links between iron and lipid metabolism in neuroblastomas have not been studied. Materials and methods We evaluated the levels and association between iron and cholesterol on in vitro neuroblastoma cancer models. Results We found that the levels of iron and cholesterol are diverse among neuroblastoma cell lines. There is a bi-directional association between iron and cholesterol in drug-resistant neuroblastoma SK-N-AS cells. In drug-resistant neuroblastoma cells, low concentration of an iron chelator did not have an impact on iron levels, but on cellular cholesterol levels. Furthermore, a cholesterol decreasing agent, simvastatin, influenced both iron and cholesterol levels in drug-resistant neuroblastoma cells. Conclusion Cholesterol decreasing agents may be more effective than iron chelators for drug-resistant neuroblastoma treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|